Impact of Methodologic Choice for Automatic Detection of Different Aspects of Brain Atrophy by Using Temporal Lobe Epilepsy as a Model
Catherine E Scanlon(University of California, San Francisco), Kenneth D. Laxer(California Pacific Medical Center), Jerome Barakos(Sutter Health), Duygu Tosun(Ministry of Health), Michael W. Weiner(University of California, San Francisco), S. G. Mueller(San Francisco VA Medical Center), P. García(University of California, San Francisco), Ian Cheong(Western University)
Cited by 32
Related Papers
Glucose Deprivation Contributes to the Development of <i>KRAS</i> Pathway Mutations in Tumor Cells
|Science|2009|908
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome
|Alzheimer s & Dementia|2018|690